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Abstract
Background: The Australian Cancer Trials website (ACTO) was publicly launched in 2010 to help people search for
cancer clinical trials recruiting in Australia, provide information about clinical trials and assist with doctor-patient
communication about trials. We describe consumer involvement in the design and development of ACTO and
report our preliminary patient evaluation of the website.
Methods: Consumers, led by Cancer Voices NSW, provided the impetus to develop the website. Consumer
representative groups were consulted by the research team during the design and development of ACTO which
combines a search engine, trial details, general information about trial participation and question prompt lists.
Website use was analysed. A patient evaluation questionnaire was completed at one hospital, one week after
exposure to the website.
Results: ACTO’s main features and content reflect consumer input. In February 2011, it covered 1, 042 cancer trials.
Since ACTO’s public launch in November 2010, until the end of February 2011, the website has had 2, 549 new
visits and generated 17, 833 page views. In a sub-study of 47 patient users, 89% found the website helpful for
learning about clinical trials and all respondents thought patients should have access to ACTO.
Conclusions: The development of ACTO is an example of consumers working with doctors, researchers and policy
makers to improve the information available to people whose lives are affected by cancer and to help them
participate in their treatment decisions, including consideration of clinical trial enrolment. Consumer input has
ensured that the website is informative, targets consumer priorities and is user-friendly. ACTO serves as a model for
other health conditions.
Background
The number of new cancer cases in Australia has more
than doubled between 1982 and 2007 [1] and clinical
trials are crucial to further progress cancer management
and survival. Consumers, led by Cancer Voices NSW
(CVN), have campaigned for many years for a national
consumer-friendly website about cancer clinical trials
which would enable consumers to undertake a compre-
hensive search for cancer trials recruiting anywhere in
Australia and thus to be able to access information about
relevant clinical trials. The need for easily accessible,
understandable and authoritative information about
treatment options, including clinical trials, for consumers
has also been acknowledged by Australian Senate
Inquiries [2] and in the National Service Improvement
Framework for Cancer [3].
Low cancer patient participation in clinical trials may
reflect lack of knowledge on the part of both doctors and
patients about relevant trials that are recruiting [4,5].
Low recruitment rates may also be the result of difficul-
ties faced by doctors in raising the option of clinical trial
participation, and by patients in deciding whether to par-
ticipate [6-8]. Evidence-based strategies are needed to
encourage participation in cancer clinical trials [9]. Con-
sumer advocates have been keenly aware of the need to
increase clinical participation, seeing consumer-friendly
information as key to achieving this goal.
Many patients also want involvement in decisions about
their health care. For example, in a heterogeneous sample
of cancer patients seeing an oncologist for the first time,
49% wanted shared decision making and 14% wanted to
take the primary role [10]. To make informed health care
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any medium, provided the original work is properly cited.choices, including whether to consent to participate in a
clinical trial, patients need good information to weigh up
their options. This need is reported as a priority by all
health consumer advocacy groups.
Up to 60% of cancer patients use the internet to seek
information about cancer, including clinical trials
[11,12]. Internet-based services to search for and provide
information about cancer clinical trials are widely avail-
able and consumer input has been used to make these
websites more user-friendly [13,14]. Online clinical trial
matching services have also been developed to help
identify potential research participants [15-18]. The
results of a number of surveys describe the willingness
of people with cancer to search for information about
cancer clinical trials on the internet [12,18-20]. The
quality of information and the user-friendliness of can-
cer websites vary [21,22]. Clearly consumers should be
able to access reliable, accurate, accessible and user-
friendly web-based information to assist them to partici-
pate in decisions about their cancer care.
Effective consumer involvement can contribute to better
health care and research and is widely recommended
[23-27]. Involvement of relevant stakeholders in the devel-
opment of websites is a much considered and researched
aspect in the field of ‘usability’ of online health resources
[28]. It is generally acknowledged that health communica-
tion benefits from materials tailored to the needs of the
target audience rather than non-tailored material [29].
To meet the demand for a consumer-friendly cancer
clinical trials website, the University of Sydney, Australian
New Zealand Clinical Trials Registry (ANZCTR), CVN
and Cancer Australia (CA) jointly developed the website
called Australian Cancer Trials (ACTO) [30]. It is a not-
for-profit national resource for people affected by cancer,
doctors and researchers. It provides a search portal for
clinical trials, information about clinical trials and trial
participation and question prompt lists (QPLs)* (see foot-
note 1).
We aim to describe the involvement of consumers in
the development of ACTO because it is an important
resource that has the potential to be replicated for other
health conditions. We also present the results of early
patient use and reactions to the website.
Methods
Consumer consultation in the design of the Australian
Cancer Trials website
The development of ACTO was informed by cancer con-
sumers. The word “consumer” is used to mean people
affected by cancer. Their involvement in this project meets
the key components outlined in the model framework for
consumer and community participation in health and
medical research developed by the Consumers’ Health
Forum of Australia and the National Health and Medical
Research Council (NHMRC) [23].
The lead consumer partner was CVN, which had
called for a national consumer-friendly cancer clinical
trials website for many years. CVN is an independent
peak consumer organisation which works to provide a
voice for people affected by cancer [31]. It is a reliable
and trusted with a proven track record of involvement
in research. For example, in partnership with the Cancer
Council NSW it developed and participated in the Con-
sumer Involvement in Research Project which provides
a set of cancer consumer criteria which should be
applied to research proposals [32] CVN also helped
develop and contributes to the Cancer Consumer Advo-
cacy Training Program [33].
The other major consumer partner was the National
Consumer Advisory Group (NCAG) which was estab-
lished in 2007 to help reduce the impact of cancer on
Australians. Members of NCAG were recruited by CA
[34], a federal government organisation, with the assis-
tance of Cancer Voices Australia and Cancer Council
Australia. It consisted of 15 consumers including repre-
sentatives from the Cancer Voices network, Aboriginal
and Torres Strait Islander representatives and three pro-
fessionals selected to provide advice and guidance to
consumers.
The impetus for the website began when SC, the chair
of CVN, met with researchers from the University of
Sydney at the end of 2006. At this time, it was proposed
that the website should be developed using data about
registered cancer trials from ANZCTR. In addition, the
researchers proposed a formal evaluation of the impact
of the website on doctor-patient discussions about trials
and accrual rates. Subsequently, in early 2007, SC with
representatives from the University of Sydney, ANZCTR
and CA formed a research team to apply for a grant
from the NHMRC to evaluate the website. In October
2007 it was announced that the grant was successful.
In her role as a research team principal investigator,
SC contacted by email the Cancer Voices chairpersons
from six Australian states and the Australian Capital
Territory asking them to nominate existing cancer trials
websites favoured by cancer consumers, key website
design features and the information required for a con-
sumer-friendly website. Three responses were received
(from Cancer Voices South Australia, Victoria and New
South Wales) and reported verbally at a meeting in
October 2007. SC recorded their views in a summary
report.
Concurrently during 2007, through NCAG’s Cancer
Voices membership, the development of a consumer-
friendly website for CA was identified as a priority at the
first meeting of NCAG. Subsequently, in consultation
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included a table of current information collected about
clinical trials from registrants and displayed on
ANZCTR. From March until May 2007 the background
paper was circulated to 50 consumers from across Aus-
tralia from CA’s network including young people affected
by cancer. Consumers were requested to identify: 1)
which of the data elements already available on the
ANZCTR should be displayed on a consumer-friendly
website and 2) what additional information would be
required to assist consumers in making decisions about
cancer clinical trials.
Twenty-one responses were received and collated into a
report. In the report, two tables were provided: 1) a list of
all the data elements consumers would need about each
cancer trial to help make an informed decision and 2)
additional consumer cancer items that needed to be col-
lected by ANZCTR to satisfy consumer needs. In addition,
the process of collecting and transferring data from
ANZCTR to the consumer-friendly website was proposed.
The second NCAG meeting in October 2007 provided
the opportunity to announce the NHMRC funding and for
SC to present her summary report. An update was given
by NCAG about their input into the website’s develop-
ment. To ensure that a consumer-friendly cancer clinical
trials website would be achieved, CA entered into a part-
nership with ANZCTR and the research team. Work was
progressed at the end of 2007 with the formation of a
Cancer Clinical Trials Website Consumer Reference
Group which had members from CVN, CA and NCAG.
This group met in January 2008 to further discuss 1) the
terms from the clinical trial registries that should be
extracted for display on ACTO; 2) the additional cancer
items needed from researchers; and 3) a conceptual out-
line for ACTO. Draft website pages were designed and
specific data elements to be included on each page were
identified. Information fields were chosen that reflected
the recommendations of the collated consumer views
about what would be helpful for people to make informed
decisions about participating in a cancer clinical trial. Con-
sumers also listed what they considered to be essential ele-
ments of the search engine for the site. These findings
were reported to the research team which, from 2008, pro-
ceeded with the website’s development in consultation
with CA, ANZCTR and a website development company.
Consumers consistently identified that a lay summary
was an essential component in the display of informa-
tion about each trial. As a result, consumers and
researchers tested a method to develop standardised lay
summaries. In June 2008, five members of the research
team wrote lay summaries for 146 cancer trials already
registered on the ANZCTR. Eleven Cancer Voices NSW
consumer representatives, who had undertaken the Can-
cer Council NSW’s Consumer Involvement in Research
Training Program (a 2-day intensive training program in
research methods and the application of lay criteria to
evaluate research protocols) [35] critiqued these summa-
ries. Their feedback indicated that the quality of the lay
summaries was mixed. Their overwhelming recommen-
dation was that the project should employ a professional
medical writer to ensure that summaries would be con-
sistent in style, phraseology and level of complexity.
Consumers agreed that the overall purpose of ACTO
was that it should be a comprehensive source of cancer
clinical trials in which consumers in Australia might
enrol. The general principles that guided this website
design were that it should be easy to read, use simple
language, have a clear format with minimal colour and
without distractions, be easy to navigate and quick to
load. The CancerHelp UK [36] and the National Cancer
Institute [37] websites werei d e n t i f i e da sc o n s u m e r -
friendly cancer clinical trial websites that were used to
guide the development of ACTO.
ACTO Evaluation
From June 2008 to October 2010 ACTO was the subject
of a large cluster randomised trial. Its aim was to evalu-
ate the effect of the website on discussions between
patients and medical oncologists about participation in
cancer clinical trials and recruitment rates to trials.
Thirty medical oncologists from 30 clinics in two Aus-
tralian states (New South Wales and Victoria) and 493
patients with cancer were recruited (full evaluation data
to be reported elsewhere). We conducted a sub-study
that recruited patients from one medical oncologist
working at a major teaching hospital in Sydney, Austra-
lia. This sub-study was completed specifically to collect
the views of an unselected sample of cancer patients
about the website. These patients were asked to com-
plete an online questionnaire (Q1) which asked demo-
graphic questions before their scheduled appointment
with their medical oncologist. After completing this
questionnaire, all patients were automatically redirected
to ACTO. One week after their consultation patients
were asked to complete a second online questionnaire
(Q2) which asked for reactions to the website. User and
hit statistics were obtained by log file analysis using
Google Analytics [38].
Statistical analyses were performed using the standard
package SAS (version 9, SAS Institute, Cary, NC, USA).
The study was approved by of the University of Sydney
(Sydney, Australia) and Royal Prince Alfred Hospital
(Sydney, Australia).
Results
The Australian Cancer Trials website
The components of ACTO that are a result of consumer
consultation are described.
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the ACTO home page. These features include 1) A
search function; 2) Information about each clinical trial;
3) Supporting information about clinical trial participa-
tion; and 4) QPLs.
As guided by consumers, ACTO meets HealthInsite
Information Partner requirements [39]. HealthInsite is a
federal government initiative which aims to provide
access to high quality information about health care to
Australians.
1 
3 
4 
2 
Figure 1 Home page of the Australian Cancer Trials website. 1. Search function, 2. Information about each clinical trial (displayed after
searching for and then selecting a trial), 3. Supporting information about clinical trial participation “About Clinical Trials”, 4. Question prompt lists.
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Consumers supported the research team’sn o v e li d e at o
use ANZCTR, which registers clinical trials, to automa-
tically download cancer trial information to ACTO.
However, it was established that only one-third of can-
cer trials conducted in Australia are registered with the
ANZCTR and approximately two-thirds are registered
with the US trial registry, ClinicalTrials.gov (CT.gov).
Thus, for ACTO to satisfy consumer demands for a sin-
gle portal of cancer clinical trials recruiting in Australia,
data needed to be sourced from both of these registries.
To achieve this, the content for ACTO is extracted
directly from ANZCTR and CT.gov via their data
exporting services and downloaded to ACTO on a
weekly basis. In contrast, static content (the content
which is unchanged week to week) is controlled by
Umbraco which is a content management system for
publishing content on the Internet. This content is only
reviewed and updated occasionally.
Cancer trial search function
As of March 2011 1, 040 cancer clinical trials are dis-
played on ACTO and approximately eight new trials are
added every month.
The elements of the search function that consumers
identified as important were 1) it should be easy to use
even by those without much computer experience; 2) a
simple and an advanced search function and; 3) the sim-
ple search should have a drop down list of cancer types
available.
The simple search page allows users to search by
either keyword (eg recurrence, early cancer) or cancer
type (using a drop-down list). The advanced search page
allows users to refine their search according to cancer
stage, phase of trial, recruitment status (open or closed)
and location of recruitment.
Consumers requested a facility for users to register for
email alerts of newly registered trials or updates about a
specific trial. ACTO is working towards providing this
service.
Information displayed about each clinical trial
The information displayed about each trial on ACTO is
shown in Table 1. All of these items were identified as
essential by consumers. Most of these details are
sourced from routinely collected data provided by trial
registrants on ANZCTR and CT.gov.
It is important to note that a lay summary of the trial,
cancer stage, anticipated end date for a trial, the cancer
treatment type, specific location of recruitment, time,
cost and travel commitments and the side effects of the
treatments in the trial are not routinely collected by
trial registries. To obtain this data, which was additional
information requested by consumers, a separate module
of “additional cancer items” was developed specifically
for registrants of cancer trials on ANZCTR (Table 2).
Now, when a cancer trial is registered on ANZCTR, the
registrant is encouraged to provide this additional infor-
mation because it enhances the consumer-friendliness of
the trial information when it is displayed on ACTO.
Consumers felt it was important that the website should
include Phase 1, 2 and 3 cancer trials as well as closed
trials. Including phase 1 trials was considered particularly
important for patients with no further standard treatment
options. Closed trials are those closed to recruitment with
follow-up continuing, or with completed follow-up.
Including closed trials means that patients who enrolled in
these trials are still able to see the trial on ACTO, and
may enable access to trial results.
In response to the consumer feedback described, all
lay summaries have been rewritten by a medical writer
who continues to write summaries for new trials as they
are registered. Summaries (and the website’ss u p p o r t i n g
information) are written for a reading age of approxi-
mately fourteen years.
Supporting information about clinical trial participation
Supporting information about clinical trial participation
(the “About Clinical Trials section of the website) was
informed by consumer recommendations (obtained as
described above) and reviewed by the ACTO research
team and a medical writer. It includes:
￿ What clinical trials are and their purpose
￿ The informed consent process
￿ Ethical issues
Table 1 Data items about each trial that are displayed on
the Australian Cancer Trials website
Data items
1. Public title
2. Recruitment status
3. Phase of trial
4. Cancer stage*
5. Lay summary written by a medical writer*
6. Description of the study
7. Target sample size
8. Primary outcome
9. Secondary outcomes
10. Side effects
11. Inclusion criteria (includes age, gender, health volunteers)
12. Exclusion criteria
13. Recruitment dates
14. Cost and time commitments*
15. Location of trial*
16. Ethics approval
17. Contacts for public and research queries
18. Trial sponsor(s)
19. Funding source(s)
*Displayed if a registrant of a cancer trial on the Australian New Zealand
Clinical Trials Registry completes the additional cancer items (Table 2).
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about becoming part of a trial
￿ Assessment issues (eligibility)
￿ Risks and benefits of participating in a trial
￿ The process of dissemination of trial results
Permission was obtained from CancerHelp UK to use
their glossary for ACTO. Over time, this has been
added to and modified.
ACTO contains two QPLs because they were identified
as a priority area for consumers at the first NCAG meeting
in March 2007 and have been shown to prompt question-
asking and increase the likelihood of people having their
information needs met [40]. Of the two QPLs developed
for the website, one is designed to help consumers ask
general questions about clinical trial participation
(‘General question prompt list: Should I consider joining a
clinical trial’, Table 3) and the second is a specific QPL
called “Should I consider joining this clinical trial?” Both
reflect consumer recommended questions and aim to help
consumers ask specific questions about a trial that is rele-
vant to their current clinical circumstances. There is a link
to the general QPL on the home page of ACTO. A link to
the specific QPL is provided next to each clinical trial
("What questions do you need to ask about this clinical
trial?”). Hyperlinks are provided from each question to
areas on the website that help to answer each question.
The QPLs can be printed. Consumers are advised to dis-
cuss the QPLs with their cancer specialist.
Website access
ACTO is currently hosted by CA. Consumer organisa-
tions are playing an integral role in the promotion and
Table 2 Additional cancer items collected by Australian New Zealand Clinical Trials Registry from registrants of cancer
trials
Data item Options
Cancer stage Early
Locally recurrent or locally advanced
Metastatic/Widespread
Not applicable
Treatment type (s) Treatment: Hormones
Treatment: Chemotherapy
Treatment: Targeted therapies and biological therapies
Treatment: Radiotherapy
Treatment: Surgery
Treatment: Other
Antiemetics
Complementary
Palliative care
Prevention/Screening
Psychosocial (counselling/training/communication/education)
Lifestyle
Rehabilitation
State (s) of recruitment The Australian state (s) where the participants are being recruited
Anticipated or actual recruitment
end date
The anticipated or actual date the trial will stop recruiting patients
Side effects The known and possible side effect (s) for each trial arm from most to least common
Cost to participants Similar cost as usual care
Less cost than usual care
More cost than usual care
Time commitments Similar time commitment as usual care
Less time commitment than usual care
More time commitment than usual care
Lay summary written by a medical
writer
Format of summary:
￿ An initial sentence summarizing the trial purpose
￿ A section describing the patient eligibility under the heading “Who is it for?”
￿ A section entitled “Trial details” which describes the trial design, intervention(s) and comparator(s) and
outcome measures of the trial
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and website links, email alerts, consumer organisation
forums and multi-disciplinary conferences.
Australian Cancer Trials website evaluation
Access statistics
To comply with the trial protocol the site was not pro-
moted during the trial period from December 2008 until
October 2010 so access statistics are reported from 1
November 2010 until 28 February 2011. 2, 549 unique visi-
tors during this period visited the website a total of 3, 342
times ACTO and generated 17, 833 page views. There were
an average of 5 pages viewed at each visit and the mean
visit duration was 3.4 minutes (range from 1 minute to 13
minutes). A planned promotional program will commence
in April 2011 so it expected these numbers will increase.
Patient evaluation
The 99 patients in the sub-study had a mean age of 53
years and 70% were female. Twenty-nine percent of
patients had breast cancer, 20% had sarcoma, 13% had
ovarian cancer and 38% had other cancer types. Of those
completing the questionnaires 47 out of 80 (59%)
patients responded that they looked at the website. Their
feedback about the website is displayed in Table 4.
Seventy percent of patients thought the search function
was easy to use, 89% thought ACTO was helpful for
learning more about cancer clinical trials and all patients
thought that it was important for patients to have access
to ACTO.
Discussion
The development of ACTO is an exemplar of a partner-
ship between consumers, clinical researchers and policy
makers to create an informative national resource about
cancer clinical trials for people affected by cancer, doc-
tors and researchers.
Although they contain valuable information, trial regis-
try websites are not always intuitive to use and are techni-
cal in nature. They do not contain related information
about clinical trial participation such as a glossary and
descriptive information about clinical trial participation.
Subsequently, ACTO has been developed using trial regis-
try data, to meet consumers’ demands for a comprehen-
sive user-friendly portal of cancer clinical trials recruiting
in Australia. It also provides supporting information that
can assist them in the decision-making process to join a
trial. To be comprehensive, ACTO obtains trial data from
both ANZCTR and CT.gov. Sourcing data directly from
these clinical trial registries is a unique feature of ACTO
and is unlike CancerHelp UK, and the National Cancer
Institute both of which maintain their own databases of
trials. This important feature increases the efficiency of
the website, minimises costs, avoids duplication, and pro-
vides good coverage of clinical trials. Furthermore consu-
m e r sw a n t e dt h es a m es o u r c eo fd a t at ob ea v a i l a b l et o
health professionals and the general public. To address all
the information consumers considered essential to making
a decision about participating in a trial, ANZCTR collects
the “additional cancer items” about registered cancer trials
Table 3 General question prompt list: should I consider joining a clinical trial?
Question category Questions
Understanding my treatment choices 1. What is the usual (standard) treatment for my condition?
2. How do I find a suitable clinical trial?
3. Who can join?
4. How do I take part?
5. How will my confidentiality be protected?
Finding out about a trial 1. How can I learn more about the trial which interests me?
Understanding the possible benefits 1. What benefits could I get by joining a trial?
2. If I join a trial, how might others benefit?
Understanding the possible risks 1. What are the general risks of being in a trial?
2. If I get a side effect or injury because of being in the trial, will I get
compensation?
The differences between going on the trial and having
standard treatment
1. What are the usual costs of being in a trial and how does this differ from
standard treatment?
Types of clinical trials and understanding ‘randomisation’ and
‘blinding’
1. What types of clinical trials are there?
2. What does randomisation mean?
3. What does blinding mean?
Understanding my right to join or not to join the trial 1. Will my doctor still treat me if I decide not to go on a trial?
2. Do I have time to think about whether to go on a trial (a day or two, or a
week?)
3. If I join the trial, but later change my mind, how can I stop?
4. Will I be penalised in any way?
Results of the trial 1. How will I be informed of the results of a trial?
2. How are the results measured?
Underlined statements indicate hyperlinks to enable website-users to find the answers to these questions on the Australian Cancer Trials website
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site’s features that were informed by consumer-input are
summarised in Table 5. Consumer-friendly websites in
other health conditions could be developed using a similar
model. We note that in 2011 the National Institute for
Health Research developed the UK Clinical Trials Gateway
which provides easy to understand information about clin-
ical trials in all health conditions using CT.gov and the
International Standardised Randomised Controlled Num-
ber Register [41,42].
To answer consumer information needs QPLs have
been developed to help patients make informed health
care choices [40]. Currently, there are no generic ques-
tion prompt lists to help consumers considering clinical
trial participation. ACTO is unique because it offers two
question prompt lists for people considering clinical
trial participation, one generic and the other specific to
the trial in question. These were modelled on a QPL
which had been developed by some of the study team
members for a large international breast cancer clinical
trial [43]. The importance of asking doctors these ques-
tions is highlighted on the website.
Worldwide, other cancer clinical trial websites have had
consumer input. The evolution and improvement of the
NCI’s online cancer information has been “user-driven”
from the launch of CancerNet in 1995 to the development
of the current NCI website [14]. The NCI has used multi-
ple approaches to gathering input including stakeholder
meetings, focus groups, online user surveys, usability test-
ing and search log analysis. Both the NCI website and
CancerHelp UK have recently upgraded their websites
based on consumer feedback. An advisory board consist-
ing of breast cancer experts and representatives from
patient support and advocacy organisations assisted with
the development of a German breast cancer trials website
[18].
Existing cancer clinical trial websites may have defi-
ciencies. The website content maybe limited, hard to
understand and often require users to have high literacy
levels [21,22,44]. Websites can be hard to navigate [22].
Table 4 Sub-study results (n = 47): reactions to the Australian Cancer Trials website
Number of
patients
Percentage
Rate the following aspects of the website:
Searching for cancer clinical trials*
Excellent/good 33 70
Neutral 4 9
Fair/poor 5 11
The information provided about the clinical trials
searched, including the lay summary**
Excellent/good 22 47
Neutral 10 21
Fair/poor 7 15
The look, feel and usability of the website***
Excellent/good 28 60
Neutral 12 26
Fair/poor 3 6
The general information about cancer clinical trials***
Excellent/good 30 64
Neutral 8 17
Fair/poor 5 11
Patients who agreed with the statements:
Helpful for learning more about cancer clinical trials 42/47 89
Would use Australian Cancer Trials in the future 28/47 60
Would recommend Australian Cancer Trials to other
patients
41/47 87
Felt it was important for patients with cancer to have
access to Australian Cancer Trials
47/47 100
* 5 did not answer ** 8 did not answer *** 4 did not answer.
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[16] and do not encourage users to consult their doc-
tors. As a result, these websites may not be fulfilling
their potential to meet consumers’ information needs.
The evidence from our study is that ACTO has over-
come these deficiencies. Although the initial evaluation
was limited by a small sample, most patients found it
easy to search for clinical trials. There appears to be suf-
ficient information on the website. It was encouraging
that all respondents thought that it was important for
patients to have access to ACTO. People are spending
3.4 minutes on average browsing ACTO, which is simi-
lar to the time spent by users of a German breast cancer
trials website (mean visit duration 3.2 minutes) [18] and
more than the time estimated that most people look at
websites [45].
ACTO has some limitations. ANZCTR and CT.gov
depend on researchers to provide accurate and up-to-
date information about registered trials [46]. Despite
b e i n gap r e c o n d i t i o nf o rp u b l i c a t i o ni na nI n t e r n a t i o n a l
Committee of Medical Journal Editors journal, not all
clinical trials are registered, so it is likely that ACTO
does not display every trial that is recruiting in Austra-
lia. Furthermore, if the additional cancer items are not
provided by registrants of cancer trials on the ANZCTR,
the trial will appear on ACTO, but these additional
fields will be blank. Similarly not all the additional can-
cer items can be sourced from CT.gov, highlighting dif-
ferences in data collection across clinical trial registries.
Every effort is being made to encourage registrants to
contribute this important information so that it can be
made available on ACTO.
Consumer involvement in health care may include
participation in research agenda setting [24], evaluating
research hypotheses [47], informally or formally evaluat-
ing grant proposals [35,48-50], communicating results
and supporting the incorporation of research findings
into practice [51,52]. The development of ACTO has
benefited from consumer involvement in each of these
areas: they have helped set the agenda for this initiative,
helped obtain research grant funding for the evaluation
of ACTO and contributed to the website’s development
and design. In collaboration with CA, who is continuing
to fund the website, consumers led by CVN are playing
an essential role in advising about the website’sp r o m o -
tion and future enhancements. For example, in colla-
boration with the research team, they have developed a
promotional plan which aims to make the relevant sta-
keholders aware of ACTO using print media, journal
articles, letters, advertisements, posters and bookmarks.
Consumers have obtained a more detailed knowledge of
trial registries and a closer relationship with the research
community as a result of their involvement. The project
has enabled opportunities for connections and informa-
tion exchange between independent consumer organisa-
tions (CVN), government organisations (CA and
NCAG), ANZCTR and the University of Sydney.
Although the development of a website required tech-
nical input, this did not hinder consumer involvement.
The research team helped consumers liaise with techni-
cal experts so that consumers’ desire for easily accessible
data about clinical trials could be achieved. In summary,
the critical success factors of this project were: (1) that
the research team has worked with well-recognised con-
sumer groups with extensive networks; (2) it was deter-
mined that a consumer-friendly cancer clinical trials
website was a priority for consumer groups and their
members and this was supported by the research team;
(3) the research team listened to the needs of consu-
mers’ and responded to their needs; and (4) the research
team assisted consumer groups to provide input when
necessary.
Conclusions
ACTO allows user-friendly access to the information
contained in two clinical trials registries, the ANZCTR
and CT.gov. Its development is an example of consu-
mers working with doctors, researchers and policy
Table 5 Summary of the Australian Cancer Trials website’s features informed by consumer-input
1. A single portal of cancer clinical trials recruiting in Australia
2. Design and features of the simple and advanced search pages
3. Information displayed about each clinical trial including:
a. Essential items to be used from clinical trial registries (Table 1)
b. “Additional cancer items” (Table 2)
4. Assistance by a medical writer to write a lay summary about each trial
5. Types of cancer clinical trials included: all trial phases, both open and closed trials
6. Information in the “About Clinical Trials” section
7. Glossary
8. Question prompt lists (see Footnote 1 and Table 3)
9. Website design: easy to read, simple language (reading age of approximately 14 years), clear format, minimal colour, easy to navigate, quick to
load
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Page 9 of 11makers to improve the information available to people
whose lives are affected by cancer and to help them
participate in their treatment decisions, including con-
sideration of clinical trials. Consumer advocacy and
input is critical to successful and relevant information
resources and has ensured that the website is informa-
tive, targets consumer priorities and is user-friendly.
ACTO can serve as a model for other health
conditions.
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Clinical Trials Registry; CA: Cancer Australia; CVN: Cancer Voices New South
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